Major news broke in the iPSC sector last week when Ncardia (Cologne, Germany) and Nanion Technologies (Munich, Germany) signed a joint marketing and sales promotion agreement. Under the terms of partnership, customers of the companies will get access to high-performance instrument platforms from Nanion, coupled with Ncardia’s portfolio of hiPSC-derived cardiac cell types and assay services. [Read more…]
NCardia, a Global Force in hiPSC Drug Discovery and Development Products and Solutions
Axiogenesis AG and Pluriomics B.V. are combining forces to form Ncardia, the new global authority in cardiac and neural applications of human induced pluripotent stem cells (iPSCs).
Ncardia established following Pluriomics Axiogenesis merger
Builds foundation to become the trusted leader in hiPSC based drug discovery solutions.
Gosselies (BE), Cologne (DE), Leiden (NL), Philadelphia (USA), September 18th 2017 – Ncardia (www.ncardia.com) has been established following the merger of Pluriomics and Axiogenesis. The privately held company with operations in Europe and the US, produces and commercializes high-quality, fully functional hiPSC derived cardiovascular and neuronal cell types and develops and realizes electrophysiology, biochemistry and contraction based assays for predictive safety pharmacology, toxicology testing and drug efficacy screenings. [Read more…]